Current Report Filing (8-k)
March 18 2013 - 4:44PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
Of Report (Date Of Earliest Event Reported): March 18, 2013
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in
Its Charter)
Delaware |
|
0-33393 |
|
94-3306718 |
(State Or Other Jurisdiction Of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
4800 Montgomery Lane, Suite 800, Bethesda,
MD 20814
(Address Of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including
Area Code (240) 497-9024
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On March 18, 2013, Northwest Biotherapeutics,
Inc. (the “Company”) issued a press release announcing that it had been issued a key U.S. patent covering novel processes
for manufacturing human dendritic cells. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form
8-K.
The information disclosed under this Item 8.01,
including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or
other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01 Financial Statements and Exhibits
| 99.1 | Press Release of Northwest Biotherapeutics, Inc. dated March
18, 2013. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC |
|
|
|
|
|
|
Dated: March 18, 2013 |
By: |
/s/ Linda Powers |
|
|
Name: Linda Powers |
|
|
Title: Chief Executive Officer and Chairman |
|
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024